For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
A short interview with Prof. John Marshall
Join Prof. John Marshall, Barts Cancer Institute, Cancer Research UK as he discusses the transformative power, challenges and key considerations of multiplex imaging with Dr. Subham Basu, Director of Strategy - Immuno-oncology, Abcam.
Learn about Cancer Research UK’s Grand Challenge initiative to decode cancer metabolism, and how multiplex imaging is changing the way that big questions in cancer biology can be answered.
About the presenters:
Prof. John Marshall
Prof. John Marshall is Professor of Tumor Biology at Barts Cancer Institute, Cancer Research UK.
He joined the laboratory of metastasis expert Ian Hart at Imperial Cancer Research Fund, London in 1984. After several years studying photodynamic therapy he began his PhD studies on the role of integrins in melanoma, discovering a novel integrin, αvβ1, that was expressed by uveal, but not cutaneous, melanomas. In the late 90’s he turned to the study of carcinoma integrins, publishing the first papers that integrin αvβ6 was a pro-invasive integrin that upregulated MMP2 and MMP9.
In 2004 he moved to Barts Cancer Institute in London where he developed a quantitative 3D organotypic invasion assay for the study of tumor-stroma interactions to help analyse integrin behaviour, which is now widely used. He has since published over 30 papers on αvβ6 showing that it represents a major target for imaging and therapy for multiple types of carcinoma.
Prof. Marshall developed an imaging agent for αvβ6 (from foot-and-mouth-disease virus) which is used for human PET imaging studies. He also co-developed a human αvβ6-blocking antibody with AstraZeneca, which entered a Cancer Research UK funded Phase I trial in pancreatic and breast cancers in 2018.
Dr. Subham Basu
Dr. Subham Basu is the Director of Strategy, Immuno-oncology at Abcam. In this role, Subham is responsible for developing and directing the commercial strategy of Abcam’s immuno-oncology portfolio. His vision is to ensure all researchers, in fundamental research, drug discovery, translational medicine and clinical science and across academia, biotech, pharma and diagnostics sectors, can access the best tools and solutions for their immuno-oncology research.
Dr. Basu has extensive experience in pharmaceutical medical affairs and market access. Prior to joining Abcam, Dr. Basu served as an advisor to the pharmaceutical and diagnostic industries as well as to venture capital funds. Having also led a competitive research laboratory at the Cancer Research UK Barts Centre he has hands-on expertise, from pre-clinical research to the commercial R&D, therapeutic and diagnostic sectors.
Powering multiplex imaging
Want to find out more on multiplex imaging? Click here.